The collective findings suggest that activation of PSAP-GPR37L1 signaling pathway has potential for clinical management of PD by ameliorating astrocytic activation, reducing αSyn pathology, and rescuing DaNs loss in PD mouse models. The gene discussed is GPR37L1; the disease is Parkinson disease.